United Therapeutics is buying back stock while it waits on two FDA filings

The technology

United Therapeutics built its business on treprostinil, a prostacyclin drug for pulmonary arterial hypertension (PAH), and has sold it in several forms: Remodulin by infusion, Nebulized Tyvaso, the dry powder Tyvaso DPI and oral Orenitram. In the second quarter those products produced most of the company's $783.3 million in revenue, with Tyvaso DPI the largest at $326.6 million.

The next products extend the same biology. Ralinepag is an oral prostacyclin receptor agonist that the company says is the first once-daily oral drug of its kind in PAH. Nebulized Tyvaso is being added to treat idiopathic pulmonary fibrosis (IPF). A separate bet is organ manufacturing: the company said it expects to launch two xeno-organ production facilities in Minnesota and Texas later this year and has clinical trials ongoing or planned for liver, kidney, heart and lung products.

The odds

Two applications are under FDA review. In June the company submitted an NDA for ralinepag, and it has submitted a supplemental NDA for Nebulized Tyvaso in IPF. The data behind them are strong. In ADVANCE OUTCOMES, ralinepag cut the risk of clinical worsening by 55% in 687 patients (hazard ratio 0.45), per the March 2 release. In TETON-1, Nebulized Tyvaso improved forced vital capacity by 130.1 mL against placebo at week 52.

Base rates favor approval at this stage. In the BIO, Informa and QLS study of 2011 to 2020, NDA/BLA to approval was 90.6% across all drugs and 93.6% in rare disease. Those figures are averages and say nothing about review timing, which the company has not given beyond saying it expects potential approvals next year.

The organ programs are far earlier. Phase 1 to approval for rare disease drugs, in the same study, was 17.0%, and organ products have no comparable approval track.

The money

United Therapeutics earned $333.0 million in the second quarter and held $3.80 billion in cash and marketable investments at June 30, with nothing drawn on a $2.5 billion revolver. It has been spending that cash on its own shares. It entered ASRs for about $1.5 billion in March, a $477.6 million ASR in September, and on Oct. 22 it authorized another $2.0 billion through Oct. 21, 2027.

Money is also coming in. Under the Oct. 13 settlement with Liquidia, United Therapeutics is due $330.4 million, of which $185 million is payable within 30 business days.

The risks

The existing business is shrinking slightly. Revenue fell 2% in both of the first two quarters of 2026. Nebulized Tyvaso dropped 18% in the second quarter, and the company says competitive therapies hurt sales of Tyvaso and Remodulin.

Regulatory risk sits with the two filings. Both rest on one company-run program each, and the FDA can ask for more data. The third risk is the Liquidia settlement itself: Liquidia may keep selling Yutrepia under its current label until the FDA approves its label change, per the 8-K, so the PH-ILD protection is not immediate.

Our read

United Therapeutics is a profitable company at an unusual moment. The legacy franchise is flat to down, but the company just won a patent fight, received strong trial data in two diseases, and submitted both applications. Management is signaling confidence by returning cash at a pace that would have been hard to imagine for a company of its size a few years ago.

The numbers to follow are the Tyvaso DPI trend, which management says exited the second quarter at record patient levels, and the FDA's handling of the two filings. If both are approved next year as the CEO expects, the company will have two new multi-hundred-million-dollar opportunities. If the review slips, a shrinking base and a large buyback would leave less room for error. Organ manufacturing is a long-dated option, not a near-term earnings driver.